Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)
Expert Opinion on Therapeutic Patents · 2023
DOI: 10.1080/13543776.2023.2201431 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Therapeutic Patents, 2023. Verfasst von Mariana Verdan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes. Universidade Federal do Rio de Janeiro - UFRJ, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Antiprotozoal Agents, Leishmaniasis, Leishmania. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 142 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Leishmaniasis is an important disease caused by parasites of the Leishmania. Due to the urgent need for financial incentives and research and development of new anti-Leishmania, a point that stands out is the creation of patents that comprise drugs and nanoformulations in treating the disease. AREAS COVERED: Information on individual patents and patent families containing potential drugs and nanoformulations were obtained by searching the Orbit software (QUESTEL SAS, France) using the following terms: Leishmania; treatment; nanoparticle*; drug×. The data obtained ranged from 2015 to 2022. EXPERT OPINION: Meglumine antimoniate is a pentavalent antimonial widely used in the classic treatment of leishmaniasis. It is part of the classic treatment recommended by WHO, being the first-choice drug globally about 75 years ago. Thus, the need to introduce new anti-Leishmania therapies into clinical medicine is evident since cases of resistance to monotherapy and multitherapy have increased greatly. Associated with this, the search for patents that are good candidates in treating this disease assues interest in investments of financial resources and raises a ray of hope for safe, effective, and low-cost therapies to become licensed for the treatment of leishmaniasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes. Universidade Federal do Rio de Janeiro - UFRJ, Rio de Janeiro, Brazil.
Zitieren
APA
Verdan, M., Taveira, I., Lima, F., Abreu, F., & Nico, D. (2023). Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2023.2201431
Vancouver
Verdan M, Taveira I, Lima F, Abreu F, Nico D. Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). Expert Opinion on Therapeutic Patents. 2023. doi:10.1080/13543776.2023.2201431
BibTeX
@article{Verdan2023,
author = {Verdan, Mariana and Taveira, Igor and Lima, Flávia and Abreu, Fernanda and Nico, Dirlei},
title = {Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)},
journal = {Expert Opinion on Therapeutic Patents},
year = {2023},
doi = {10.1080/13543776.2023.2201431}
}
EUVIMED